Updates are available Correction dated 2021-04-06
Click to view Correction: https://doi.org/10.1186/s13023-021-01787-4
-
Authors
Terrier, Benjamin
Darbon, Raphaël
Durel, Cécile-Audrey
Hachulla, Eric
Karras, Alexandre
Maillard, Hélène
Papo, Thomas
Puechal, Xavier
Pugnet, Grégory
Quemeneur, Thomas
Samson, Maxime
Taille, Camille
Guillevin, Loïc
,
Audard, Vincent
Aumaitre, Olivier
Briot, Karine
Cacoub, Patrice
Cathebras, Pascal
Chauveau, Dominique
Chosidow, Olivier
Chouchana, Laurent
Cottin, Vincent
Cornec, Divi
Daugas, Eric
Diot, Elisabeth
Dupin, Nicolas
Karoui, Khalil El
Fain, Olivier
Gobert, Pierre
Guilpain, Philippe
Hamidou, Mohamed
Hummel, Aurélie
Jachiet, Marie
Jouneau, Stéphane
Chiche, Noémie Jourde
Landron, Cédric
Le Jeunne, Claire
Lega, Jean-Christophe
Mariette, Xavier
Morel, Nathalie
Pagnoux, Christian
Remy, Philippe
Vandergheynst, Frédéric
- License Information
-
More Information
Article History
First Online: 29 December 2020
Change Date: 6 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13023-021-01787-4
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: BT reports consulting fees from Roche, AstraZeneca, and Roche-Chugai; speaking fees from Grifols. RD reports no conflicts of interest. CD reports no conflicts of interest. EH reports consulting fees from Actelion, Boehringer Ingelheim, Bayer, GSK, Roche-Chugai, Sanofi-Genzyme; speaking fees from Actelion, GSK, Roche-Chugai; and research funding from Octapharma, CSL Behring, GSK, Roche-Chugai, and Actelion. AK reports speaking fees from Roche. HM reports consulting fees from Amicus Therapeutics, Shire; speaking fees from Sanofi-Genzyme, Amicus Therapeutics. TP reports speaking fees from GSK, Ferring. XP has been an investigator in academic studies for which rituximab was provided by Roche Pharma; has declared speaking fees and honoraria (Boehringer Ingelheim, Sanofi, Pfizer, LFB), and congress inscription/travel/accommodation (Sanofi). GP reports no conflicts of interest. TQ reports research funding from Chemocentryx. MS reports consulting fees from Roche-Chugai; speaking fees from Roche-Chugai. CT reports consulting fees from Sanofi, GSK, Novartis, AstraZeneca; speaking fees from GSK, Sanofi, AstraZeneca; and research funding from GSK. LG reports consulting fees from Janssen, Lilly Pharma, AstraZeneca.
